YPrime Investing Further in Data and AI Initiatives,
Names Greg Wellbrock Chief Data and AI Officer
New executive role formalizes leadership of accelerating delivery, strengthening study data, and advancing intelligent clinical trial execution
MALVERN, PA – October 20, 2026 – YPrime, a leading clinical trial technology company delivering eCOA, IRT, and eConsent solutions, today announced the acceleration of its data and artificial intelligence initiatives and the appointment of Greg Wellbrock as Chief Data and AI Officer.
The move reflects YPrime’s continued investment in technologies transforming clinical trial execution and formalizes Wellbrock’s leadership of the company’s data, architecture, and AI strategy. As sponsors and CROs face increasing pressure to improve efficiency, accelerate timelines, and gain faster access to actionable study data, YPrime is expanding its focus on intelligent automation, real-time data connectivity, and AI-enabled innovation across its solutions and operations.
“Clinical research is entering a new era where the value of data depends on how quickly and effectively it can be transformed into action,” said David Wallace, Chief Technology Officer at YPrime. “Sponsors need technology partners that can deliver connected, high-quality data while helping their teams execute with greater speed and confidence. Greg has been instrumental in building that foundation at YPrime, and this appointment reflects the strategic role data and AI will continue to play in our growth and in the success of our customers.”
YPrime’s data and AI initiatives help sponsors unlock greater value from clinical trial data through enhanced interoperability, intelligent automation, and AI-enabled workflows designed specifically for regulated clinical research environments. By strengthening how data flows across participants, sites, sponsors, CROs, and systems, YPrime improves visibility, streamlines operations, and enables faster decision-making throughout the study lifecycle.
Those efforts are already delivering measurable results. Since joining YPrime more than two years ago, Wellbrock has led the company’s data organization while guiding its AI initiatives. AI-supported processes have helped YPrime accelerate study configuration, streamline the implementation of mid-study protocol changes, and deliver product enhancements on compressed timelines while maintaining the high-quality standards required in clinical research.
“AI in clinical research only creates value when it is built on a foundation of trusted, high-quality data,” said Wellbrock. “Our focus is not AI for its own sake. It is about helping sponsors gain faster access to reliable information, automate routine processes, reduce execution risk, and make better decisions throughout a study. Bringing data and AI together under a unified strategy allows us to deliver even greater value for our customers.”
Security, compliance, and responsible innovation remain central to YPrime’s approach. YPrime does not use sponsor clinical data in AI initiatives unless explicitly directed by the sponsor or CRO and applies AI in alignment with evolving regulatory guidance, customer security requirements, and industry best practices.
YPrime’s commitment to innovation continues to earn industry recognition. The company was recently named to Everest Group’s Top 50™ Pharmaceutical Technology Providers 2026, recognized as a Leader in the Everest Group 2025 eCOA PEAK Matrix® Assessment, and received two 2025 Clinical Trials Arena Excellence Awards, including recognition for Innovation in AI for Clinical Trials.
To learn more about YPrime’s AI-powered eCOA, IRT, and eConsent solutions, visit www.yprime.com.
About YPrime
YPrime simplifies clinical trials with eCOA, IRT, and eConsent solutions that combine speed, flexibility, and quality. The YPrime eCOA platform enhances participant compliance through an intuitive app, streamlines site workflows through a powerful portal, integrates with connected devices, and provides sponsors with real-time data for informed decision-making. AI-supported eCOA localization accelerates globalization, while pre-validated and configurable eCOA, along with robust IRT capabilities, enable faster study startup with quality metrics above industry standards. Trusted by top pharma leaders and emerging biotech companies alike, YPrime brings deep industry expertise to deliver reliable, scalable solutions. With nearly two decades of experience, solutions in 250+ languages, and support in 100+ countries, YPrime helps solve clinical research challenges with certainty. To learn more, visit www.yprime.com.
Media Contact
Grazia Mohren
Senior Vice President, Marketing, YPrime
marketing@yprime.com